 |
[Apha Biz=(Chicago) Reporter Paul Lee] Seegene announced on November 11 that it had sales of 84.928 billion won and operating loss of 9.6 billion won in the second quarter. The operating loss was reduced from the first quarter (-13.7 billion won).
In fact, sales of non-corona such as respiratory viruses and human papillomavirus (HPV) increased by 7% and 44%, respectively, compared to the same period last year. Currently, non-corvina products account for 60% of total sales and 75% of reagent sales, and sales of corona products account for about 12% of total sales.
Seegene continues non-corona product research and development (R&D) and is also empowering CGEN's 'global sharing business'. The global sharing project refers to a project to distribute CGEN's gene amplification (PCR) diagnostic know-how to global diagnostic companies for free and develop and produce locally customized products. The global copyright of the developed product will be held by Cgen. In the first half of this year, it signed a business agreement with two Israeli bio companies, HiLab and Spanish diagnostic company Wepen.
The Seegene aims to enter into business agreements with European countries such as Britain and France in the second half of this year. It plans to expand its partner countries to more than 100 by 2028 and is also preparing for mergers and acquisitions (M&A).
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
